1-14 of 14 results for subject:Streptococcus
Librarians' tools
- Search time
- 0.253 seconds
- Solr query time
- 0.028 seconds
- Search query
- subject:Streptococcus
- We searched for
- subject_t:Streptococcus OR subject_t:"Strep A" OR subject_t:"Streptococcal infections" OR subject_ses:368447
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, if he will publish the outcome of the UK National Screening Committee Group B Streptococcus trials completed in 2024.
To ask the Secretary of State for Health and Social Care, if he will publish the outcome of the UK National Screening Committee Group B Streptococcus trials completed in 2024.
The UK National Screening Committee does not run its own trials. The committee is currently awaiting the findings of an independent trial into Group B Streptococcus, which concluded its recruitment phase in 2024. Neither the committee nor my Rt Hon. Friend, the Secretary of State for Health and Social Care have any influence over the date of publication for this independent trial.
To ask the Secretary of State for Health and Social Care, when he expects to receive the outcome of the Group B Streptococcus trial from the UK National Screening Committee.
To ask the Secretary of State for Health and Social Care, when he expects to receive the outcome of the Group B Streptococcus trial from the UK National Screening Committee.
Recruitment to the Group B Streptococcus trial undertaken by the University of Nottingham has ended. The researchers are analysing the data and will draft a report in due course.
The UK National Screening Committee’s Secretariat is in close and regular contact with the researchers. The committee will review the evidence from the trial, once the report is available.
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 15 January 2024 to Question 8936 on Streptococcus: Screening, when he expects to receive the response of the UK National Screening Committee's findings on the outcome of the Group B Streptococcus trials.
To ask the Secretary of State for Health and Social Care, with reference to the Answer of 15 January 2024 to Question 8936 on Streptococcus: Screening, when he expects to receive the response of the UK National Screening Committee's findings on the outcome of the Group B Streptococcus trials.
The National Institute for Health and Care Research (NIHR) funded the GBS3 trial. It is looking at whether testing all pregnant women for Group B Streptococcus and giving them antibiotics reduces the risk of infection in newborn babies, compared to the current strategy in place in the United Kingdom. The current strategy in the UK is to offer antibiotics during labour to women who are considered at raised risk of their baby developing a Group B Streptococcus infection.
Recruitment to the trial ended in May 2024. The researchers are analysing the data, and a report is expected in Summer 2025. The UK National Screening Committee Secretariat is in close and regular contact with the researchers. The committee will review its recommendation considering the evidence from the trial, after the report is presented.
To ask the Secretary of State for Health and Social Care, whether she expects to receive the outcome of the Group B Streptococcus trial before the House rises for the Summer adjournment.
To ask the Secretary of State for Health and Social Care, whether she expects to receive the outcome of the Group B Streptococcus trial before the House rises for the Summer adjournment.
The clinical and cost-effectiveness of testing for Group B Streptococcus: a cluster randomised trial with economic and acceptability evaluations trial current contract end date is 31 August 2025, therefore results will not be available before the House of Commons rises for the summer adjournment. The trial has finished recruiting participants and data extraction and analysis continues and the results will be available once both are completed. As with all research funded through the National Institute for Health and Care Research, we expect findings to be submitted to the Department, and in the case of this trial, to the UK National Screening Committee (UK NSC) hosted by the Department. The UK NSC stands ready to review the findings of this research as soon as the results are shared.
To ask the Secretary of State for Health and Social Care, when she expects to receive the Group B Streptococcus cluster randomised trial results.
To ask the Secretary of State for Health and Social Care, when she expects to receive the Group B Streptococcus cluster randomised trial results.
I refer the Hon. Member to the answer I gave on 15 January 2024 to Question 8936.
To ask the Secretary of State for Health and Social Care, to the Answers of 20 December 2022 to Question 102798 and of 4 September 2023 to Question 194994 on Streptococcus: Screening, what her planned timetable is to respond to the cluster randomised trial on Group B Streptococcus expected to...
To ask the Secretary of State for Health and Social Care, to the Answers of 20 December 2022 to Question 102798 and of 4 September 2023 to Question 194994 on Streptococcus: Screening, what her planned timetable is to respond to the cluster randomised trial on Group B Streptococcus expected to...
The clinical and cost-effectiveness of testing for Group B Streptococcus: a cluster randomised trial with economic and acceptability evaluations (GBS3) trial is currently recruiting participants. The trial is currently contracted to complete at the end of May 2024. As with all research funded through the National Institute for Health and Care Research, we expect findings to be submitted to the Department; in the case of this trial, to the UK National Screening Committee (UK NSC) hosted by the Department. The UK NSC stands ready to review the findings of this research as soon as the results are shared.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December to Question 102798 on Streptococcus: Screening, whether he expects the Group B Strep trial to report before the end of 2024.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December to Question 102798 on Streptococcus: Screening, whether he expects the Group B Strep trial to report before the end of 2024.
The clinical and cost-effectiveness of testing for Group B Streptococcus: a cluster randomised trial with economic and acceptability evaluations (GBS3) trial is currently still recruiting participants. We expect these findings, as with all research funded via the National Institute for Health and Care Research, to be published following a full analysis of the trial data.
To ask the Secretary of State for Health and Social Care, whether he expects the Group B Strep trial to report before early 2025.
To ask the Secretary of State for Health and Social Care, whether he expects the Group B Strep trial to report before early 2025.
Group B Streptococcus: a cluster randomised trial with economic and acceptability evaluations is expected to end on 31 May 2024 and findings will be reported following a full analysis of the trial data.
To ask the Secretary of State for Health and Social Care, whether the National Institute for Health Research is on schedule to report the results of clinical trials on universal screening for Group B Strep during pregnancy in 2023.
To ask the Secretary of State for Health and Social Care, whether the National Institute for Health Research is on schedule to report the results of clinical trials on universal screening for Group B Strep during pregnancy in 2023.
The trial was paused last year due to the pandemic and it is now expected that the results will be in the public domain in early 2025.
To ask the Secretary of State for Health and Social Care, what the timetable is for the Group B Strep trial to report.
To ask the Secretary of State for Health and Social Care, what the timetable is for the Group B Strep trial to report.
The trial was paused last year due to the COVID-19 pandemic and it is now expected that the results of the trial will be in the public domain in early 2025.
To ask the Secretary of State for Health how he plans to improve care for expectant mothers and reduce the risk of group B streptococcal infection in new born babies.
[146809]
To ask the Secretary of State for Health how he plans to improve care for expectant mothers and reduce the risk of group B streptococcal infection in new born babies.
[146809]
The Royal College of Obstetricians and Gynaecologists (RCOG) published its updated guideline on the prevention of early onset neonatal group B streptococcal (GBS) disease in July 2012. The updated guideline took into account new evidence on the prevention of early-onset neonatal GBS disease. It is important that services undertake local clinical, audits to ensure the effective use of intrapartum antibiotic prophylaxis recommended by the guideline.
In 2012 the National Institute for Health and Clinical Excellence published two clinical audit tools which include clinical audit standards, a data collection form and an action plan template for use by services that care for women in labour or for babies at risk of, or being treated for, early on-set neonatal infection.
The Department is working together with the national health service, RCOG, the Royal College of Midwives, the National Institute for Health Research Heath Technology Assessment and the pharmaceutical industry on a number of areas:
the topic of a “point of care” test so that high-risk women, as identified in the RCOG revised Green-Top guideline on the prevention of early-onset neonatal GBS disease, can be tested at the start of labour is currently in the Health Technology Assessment prioritisation process and will be worked up for discussion in terms of relative importance, feasibility and noting any other existing and on going research;
development of an implementation tool for use locally to audit current practice and improve implementation of the revised RCOG guideline on the prevention of early-onset neonatal GBS disease;
including GBS as a topic within education and continuing professional development programmes for midwives and other clinicians; and
monitoring developments on vaccines against GBS infection.
That this House notes that Group B Streptococcus (GBS) is the most common cause of life-threatening infection in newborn babies in the UK and that, without preventative action, 1 in 1,000 newborn babies will develop GBS infection, of whom approximately 75 will die and 40 will survive with long-term problems; congratulates Group B Strep Support, the UK's only charity focussed on GBS infection in newborn babies, on organising the UK's first Awareness Week from 26th September to 2nd October to increase knowledge of how most GBS infections in babies can be prevented; recognises that effective local implementation of the Royal College of Obstetricians and Gynaecologists' November 2003 Guideline No. 36 (prevention of early-onset neonatal group B streptococcal disease) will prevent most GBS infection in newborn babies and implores the Government to facilitate full implementation; expresses its concern that reliable testing for GBS carriage in pregnancy, recognised by the Royal College of Obstetricians and Gynaecologists' guideline as optimal, is still unavailable on the NHS; urges the Department of Health to ensure it is available urgently; and further notes that the recent article by the Medical Screening Society Working Group on GBS disease, comprising independent international and UK experts, supports both the efficacy of screening and the need for a vaccine.
That this House notes that Group B Streptococcus (GBS) is the most common cause of life-threatening infection in newborn babies in the UK and that, without preventative action, 1 in 1,000 newborn babies will develop GBS infection, of whom approximately 75 will die and 40 will survive with long-term problems;...
That this House welcomes the Royal College of Obstetricians and Gynaecologists Guideline No 36 on group B streptococcus (GBS); recognises that GBS is the UK's most common cause of life-threatening infection in newborn babies, causing septicaemia, pneumonia and meningitis in an estimated 700 babies per year, killing 100 of these sick babies and leaving 35 survivors with long-term problems including brain damage; recognises that the implementation of the Guideline throughout UK maternity units would significantly reduce the incidence of neonatal GBS infection; calls on the Government to ensure that this guideline is used to inform every maternity unit's protocol for preventing GBS infection; and further calls on the Government to make reliable tests for diagnosing GBS colonisation, as recognised in the Guideline and as available in other European countries, the US and Australasia, available to pregnant women in the UK, so that more pregnant women whose babies are at raised risk from GBS can be identified and more of these devastating infections can be prevented.
That this House welcomes the Royal College of Obstetricians and Gynaecologists Guideline No 36 on group B streptococcus (GBS); recognises that GBS is the UK's most common cause of life-threatening infection in newborn babies, causing septicaemia, pneumonia and meningitis in an estimated 700 babies per year, killing 100 of these...
That this House notes that an estimated 3,500 mothers in the UK in the last five years have suffered the pain and trauma of their baby developing life-threatening Group B Streptococcal (GBS) infections, including septicaemia, pneumonia and meningitis; further notes that approximately 500 of these sick babies have died, and a further 200 of the survivors have been left with consequences including brain damage; recognises that GBS infections and deaths can be drastically reduced by adopting screening programmes for all pregnant women and taking precautionary action, usually giving intravenous anti-biotics during labour to women found to carry GBS and those with recognised risk factors; understands that screening programmes and other measures have been adopted and found to work in other European countries and the US; and calls on the Government to investigate instigating similar schemes in the UK as a matter of urgency.
That this House notes that an estimated 3,500 mothers in the UK in the last five years have suffered the pain and trauma of their baby developing life-threatening Group B Streptococcal (GBS) infections, including septicaemia, pneumonia and meningitis; further notes that approximately 500 of these sick babies have died, and...